Research programme: cannabinoid receptor modulators - Sunovion Pharmaceuticals/IntelGenx

Drug Profile

Research programme: cannabinoid receptor modulators - Sunovion Pharmaceuticals/IntelGenx

Alternative Names: CAT 210; CAT 320; INT 0014/2008; Modulyn

Latest Information Update: 25 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cannasat Therapeutics
  • Developer Cynapsus Therapeutics; IntelGenx Corp.
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Anxiety disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 25 Oct 2016 Cynapsus Therapeutics has been acquired by Sunovion Pharmaceuticals
  • 31 Dec 2008 Preclinical trials in Schizophrenia in Canada (PO)
  • 07 Nov 2006 Preclinical trials in Chemotherapy induced nausea and vomiting in Canada (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top